GNRH1 and neoplasm: Table 3 shows the proportion of incident GnRH agonist users with various diagnoses and procedures within 3 months before or after diagnosis of prostate cancer, comparing those with a diagnosis of prostate cancer from a SEER tumor registry versus those with a diagnosis based only on Medicare claims.